Recent momentum across the life sciences ecosystem spans international enterprise building, massive artificial intelligence financing, and oncology trial progress. While venture creation platforms broaden their geographical reach, AI drug developer Isomorphic Labs bolstered its balance sheet by closing a $5 billion private financing round. Meanwhile, Sellas Life Sciences posted positive data for an experimental blood cancer immunotherapy. This candidate achieved a 41% reduction in the risk of death compared to standard care for patients diagnosed with advanced acute myeloid leukemia.
Key points
Global venture creators are actively broadening their operational footprints to launch no…: Global venture creators are actively broadening their operational footprints to launch novel life sciences enterprises abroad.
Large-scale private funding rounds continue to flow directly into artificial intelligence…: Large-scale private funding rounds continue to flow directly into artificial intelligence drug development platforms.
Emerging blood cancer therapies are demonstrating significant clinical potential to impro…: Emerging blood cancer therapies are demonstrating significant clinical potential to improve survival outcomes over existing care standards.
Sources checked by our analysis pipeline: 1
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. We’ve got a lot of news to get into today, including some big developments in oncology.
The need-to-know this morning
- Isomorphic Labs, the AI drug developer, raised $5 billion in private financing.
Sellas’ blood cancer immunotherapy cut risk of death
An experimental drug from Sellas Life Sciences reduced the risk of death by 41% compared to standard treatment for patients with an advanced stage of acute myeloid leukemia, the company said this morning.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
The United States officially lost its measles elimination status on Tuesday as the country grapples with multiple outbreaks of the virus. The surge comes amid falling vaccination rates, creating significant costs and public health consequences for Americans.
Health officials made the formal determination after the same viral strain spread continuously across the nation for more than twelve months. The setback reflects declining immunization rates driven by post-pandemic misinformation and eroded trust in public medical guidance. At the same time, top federal leaders are actively reshaping health policy and publicly challenging long-established immunizations.
Global health officials finalized the decision following a devastating resurgence fueled by prolonged misinformation and declining immunization rates. The return of endemic transmission after 26 years exposes the public to severe disruptions, including heightened infection risks and mandatory 21-day quarantines. Regaining the nation's previous status will now demand dedicated congressional funding alongside an aggressive, coordinated national response.